LN229-Luc

LN229-Luc is a bioluminescent derivative of the human LN229 glioblastoma cell line, engineered to stably express a firefly luciferase reporter gene. The parental LN229 cell line was established from a glioblastoma of the right frontal parieto-occipital cortex in a 60-year-old female patient and is widely used as a preclinical model of glioblastoma multiforme (GBM). LN229 cells exhibit epithelial morphology and harbor key molecular alterations characteristic of glioblastoma, including PTEN loss and activation of the PI3K/AKT signaling pathway, while retaining wild-type EGFR status. These features make LN229 a valuable model for studying GBM pathogenesis, signaling pathway dependencies, and responses to targeted and cytotoxic therapies.

The stable luciferase integration in LN229-Luc enables sensitive, noninvasive bioluminescence imaging (BLI) of tumor burden in orthotopic intracranial and subcutaneous xenograft models in immunocompromised hosts. The emitted luminescent signal correlates with viable tumor cell number, supporting longitudinal monitoring of tumor engraftment, intracranial growth, and therapeutic response without repeated invasive procedures. LN229-Luc is particularly suited for evaluating blood-brain barrier-penetrant agents, temozolomide combinations, targeted PI3K/mTOR inhibitors, and immunotherapy approaches in preclinical GBM research.

LN229-Luc retains the established biological and molecular properties of the parental LN229 line, providing a relevant platform for glioblastoma drug development and mechanistic studies. The luciferase reporter substantially enhances experimental sensitivity and enables real-time longitudinal pharmacodynamic assessment of treatment efficacy in live animal models. Researchers should validate luciferase activity, growth kinetics, and molecular phenotype under their specific experimental conditions prior to large-scale preclinical use.

37°C, 5% CO₂, humidified atmosphere.

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

7. Follow the procedure described under Post-Thaw Recovery

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.